Objective: Open-source automated insulin delivery (AID) pre-dated the availability of commercial systems and is used by thousands of people with T1D despite no regulatory approval. Our objective was to examine efficacy and safety of open-source AID.

Methods: A 24 week, multi-center RCT in children (7-15 years) and adults (16-70 years) with T1D comparing open-source AID (using the OpenAPS algorithm from a version of AndroidAPS implemented in a smartphone with the DANA-i™ insulin pump and Dexcom G6® CGM) , to sensor augmented pump therapy (SAPT) . The primary outcome was change in the percent of time in target sensor glucose range (TIR; 3.9-10mmol/L) from run-in to the last two weeks of the RCT.

Results: Ninety-seven patients (48 children and 49 adults) were randomized. Glycemic data are shown in table 1. Mean TIR (±SD) at study end was 74.5±11.9% using AID (Δ+ 9.6±11.8% from run-in; P<0.001) for adults, and 67.5±11.5% (Δ+ 9.9±14.9% from run-in; P<0.001) for children. Mean TIR at study end for the SAPT arm was 56.5±14.2% and 52.5±17.5% for adults and children respectively, with no change from run-in. No severe hypoglycemic or DKA events occurred in either arm. Two participants withdrew from AID due to hardware issues.

Conclusion: Open-source AID using the OpenAPS algorithm within a version of AndroidAPS, a widely used open-source AID solution, appears safe and effective.


M.J. Burnside: None. D.M. Lewis: None. H. Crocket: None. R. Meier: None. J. Williman: None. O.J. Sanders: None. C.A. Jefferies: None. A.M. Faherty: None. R. Paul: Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk. C.S. Lever: None. B.J. Wheeler: Research Support; Dexcom, Inc., i-SENS, Inc., Medtronic. T. Gunn: Other Relationship; Sooil Development Co. C. Lampey: None. M. de Bock: Research Support; Dexcom, Inc., Medtronic, Novo Nordisk, SOOIL, Ypsomed AG. Speaker's Bureau; Ypsomed AG.


Health Research Council of New Zealand (19/481 and 21/001)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.